Current treatment techniques for brain metastases

15th January 2021  09:00 - 17:00 (GMT+00:00) GMT

CPD: 5 points

This one-day event will bring together leaders in the treatment of brain metastases and will inform best practice and provide practical approaches to overcoming clinical challenges. This event will create a forum where specialists can educate and inform on their practice and techniques whilst gaining a fresh insight into the solutions of others. Novel research and development ideas will be discussed at this meeting.

There will be opportunities for networking and collaboration amongst experts. The latest solutions from industry leaders will also be available to delegates, helping them to remain informed on the latest technological advances. A debate around the question “Is SRS always the preferred treatment option over whole brain radiotherapy?” will provide an opportunity for delegate participation with the polling of opinion before and after the debate.

We are offering delegates £25 off the ticket price for this event using the code RT25 T&Cs apply*.
(*The discount cannot be used on previous bookings or in combination with any other discount and cannot be used on student or retired member registrations). 

View full programme

Poster submissions
We are inviting researchers to submit posters (size A0 and portrait orientation) relating to current treatment techniques for brain metastases for display on the wall in the lecture theatre. This is an opportunity to share your latest advances and developments with colleagues who are actively involved in this discipline. There will be a 10 minute poster viewing session just before lunch. Please email if you would like to submit a poster for exhibition at this event. Limited poster spaces available, so please do send your poster as soon as possible. 

Please note, you will need to bring your poster during the registration period on 15 January and we will assist you in putting this up for display. Please be aware that you need to register and attend the event to have the opportunity of presenting your poster. Please register for this event as soon as possible as your space is not guaranteed until you have registered.

Educational aims:

  • To inform on best practice from leaders in the treatment of brain metastases
  • To create opportunities for discussion with leading experts
  • To provide an interactive debate on the question “Is SRS always the preferred treatment option over whole brain radiotherapy?”

Registration Fees
BIR Member Plan 1 £185
BIR Member Plan 2 £125
BIR Trainee member £125
BIR Retired/Student member £65
Non member £295

Photography disclaimer 
The British Institute of Radiology may take photos at events. These images will be used by the BIR to share news about the event and to publicise upcoming events. Images may be used in press releases, printed publicity and published on the website and social media. They will be stored securely, and will be deleted after they are no longer needed for publicity purposes. 

Please note, by registering for a BIR event you are giving consent for your photo to be used by the BIR for marketing and publicity purposes. If you would prefer not to be photographed, please email the BIR events team or speak to a member of staff on the day.




We are very grateful to the following organisations for supporting this event.

Advanced Accelerator Applications

Advanced Accelerator Applications, S.A. (AAA), a Novartis company, is an innovative medicines company developing targeted radioligand therapies and precision imaging radioligands for oncology. We are committed to transforming patients’ lives by leading innovation in nuclear medicine. AAA currently has over 1,000 employees working across 31 sites in 12 countries (Canada, France, Germany, Israel, Italy, the Netherlands, Poland, Portugal, Spain, Switzerland, the UK and the US). The company also has global manufacturing capabilities with 19 facilities in eight countries, and six research & development sites. For more information, please visit:

Bayer Healthcare

Bayer’s Radiology business is well placed to be the partner of choice in helping NHS trusts to address the many challenges faced today including the increasing need for governance to demonstrate best practice and improving patient care within increasing financial constraints. With market-leading contrast media and power injector systems, Bayer is able to offer innovative patient care and with the addition of its informatics platform, it can support radiology departments in driving protocol standardisation and easily accessible audit data that enable departments to meet further challenges faced around contrast and radiation dose management. 0118 2063999

Elekta Ltd

GE Healthcare Ltd

GE Healthcare is a leading provider of medical imaging, monitoring, and life science technologies. GE Healthcare enables precision health in diagnostics, therapeutics and monitoring through intelligent devices, data analytics, applications and services to help providers, researchers and life sciences companies in their mission to improve outcomes for patients around the world.

Oncology Imaging Systems

Oncology Systems Limited

Philips Healthcare

Enabling better health and better care at lower cost Philips is a leading health technology company focused on improving people`s lives across the health continuum - from healthy living and prevention, to diagnosis, treatment and home care. Applying advanced technologies and deep clinical and consumer insights, Philips delivers integrated solutions that improve people`s health and enable better outcomes. Partnering with its customers, Philips seeks to transform how healthcare is delivered and experienced. The company is a leader in diagnostic imaging, image-guided therapy, patient monitoring and health informatics, as well as in consumer health and home care.


Siemens Healthineers

At Siemens Healthineers, our purpose is to enable healthcare providers to increase value by empowering them on their journey towards expanding precision medicine, transforming care delivery, and improving patient experience, all enabled by digitalising healthcare. An estimated 5 million patients globally everyday benefit from our innovative technologies and services in the areas of diagnostic and therapeutic imaging, laboratory diagnostics and molecular medicine, as well as digital health and enterprise services. We are a leading medical technology company with over 170 years of experience and 18,000 patents globally. With more than 48,000 dedicated colleagues in 75 countries, we will continue to innovate and shape the future of healthcare. For more information and latest product line, please visit